retatrutide fat loss clinical trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a ๐ RETATRUTIDE PHASE 3 RESULTS:
Description
Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension
Together, these hormones coordinate to regulate appetite, insulin and glucagon secretion, and nutrient metabolism, making them central to metabolic health
Br J Nutr 92:521526
A.MorganD
